Juan José Vázquez-Vicente

Mr. Juan José Vázquez-Vicente

Agencia Pública Sanitaria Poniente
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
JTJuan José Tejada-Pérez
Juan José Tejada-Pérez
Juan José Vázquez-VicenteJuan José Vázquez-Vicente
Juan José Vázquez-Vicente
MHMaría Renée Herrera-Burgos
María Renée Herrera-Burgos
Francisco Gabriel Martin-MartinFrancisco Gabriel Martin-Martin
Francisco Gabriel Martin-Martin
TPTesifón Parron
Tesifón Parron
RARaquel Alarcón
Raquel Alarcón
Hepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with Engerix B® lowers this risk by providing workers with immunity to the virus. However, through the years, we have encountered nonresponsive health personnel to the Engerix B® vaccine; hence, the Occupational Health Service of Poniente Hospital studied the Fendrix® adjuvanted vaccine as an alternative vaccine to develop immunological responses in healthcare workers who do not respond to vaccination with Engerix B®. In our study, we employed a vaccination schedule with the Fendrix® vaccine, performing serology tests on the cases after the application of each dose. The results obtained showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after the first doses. These encouraging results support the future inclusion of this vaccine as one possible alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B®.